Oral Pulse Azithromycin versus 6-week Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: Randomised Clinical Trial

Phase 4

Completed

• Conditions: Moderate to Severe Meibomian Gland Dysfunction; MGD, Moderate to Severe MGD, Moderate to Severe Meibomian Gland Dysfunction

• Registration Number: TCTR20180810001
• Lead Sponsor: Faculty of medicine, Chiang Mai university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-10
• Study Completion: 2022-05-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Moderate to severe MGD patients (over the age of 18 years) who had not responded to conservative management: eyelid warming/massage/cleaning (4-5 min) twice a day and artificial tears (at least four times a day)

Exclusion Criteria

1.History of vernal and atopic keratoconjunctivitis
2.History of rosacea
3.Altered lid anatomy
4.History of ocular and ocular adnexal surgery or punctual occlusion
5.Had taken systemic or topical antibiotics or retinoic acid or using topical anti-inflammatory medication (steroids or cyclosporin) within 1 month prior to the enrollment
6.Allergy to azithromycin, erythromycin, tetracycline or macrolide group
7.History of side-effect symptoms from the previous use of azithromycin or doxycyline or macrolides that persist or affect daily life
8.History of liver disease, renal disease, arrythmia or HIV infection
9.Pregnancy or breast feeding or plan to pregnant within 3 months
10.Contact lens use within 3 month prior to inclusion
11.Inability to comprehend the informed consent or complete the requested therapy and follow-up
12.Reject to sign an inform consent form

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of oral pulse azithromycin and doxycycline Pre-treatment and at 8th week after treatment Reduction of score (6-sign score, 5-symptom score and total score)

Secondary Outcome Measures

Name	Time	Method
Satfy of oral pulse azithromycin and doxycycline Pre-treatment, 6th and 8th week after treatment Presence of signs or symptoms